Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 249,872 shares of the life sciences company’s stock after selling 11,429 shares during the quarter. Principal Financial Group Inc. owned approximately 0.32% of Integra LifeSciences worth $10,882,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of IART. Signaturefd LLC increased its stake in shares of Integra LifeSciences by 248.5% during the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after buying an additional 415 shares during the period. Hexagon Capital Partners LLC boosted its holdings in shares of Integra LifeSciences by 123.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 370 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Integra LifeSciences during the third quarter worth $47,000. Covestor Ltd lifted its holdings in shares of Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 921 shares during the period. Finally, International Assets Investment Management LLC acquired a new stake in shares of Integra LifeSciences during the fourth quarter worth $190,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

IART has been the subject of a number of recent analyst reports. Citigroup raised their target price on Integra LifeSciences from $24.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, May 22nd. JMP Securities lowered their price target on Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a report on Tuesday, May 7th. Morgan Stanley decreased their target price on Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating for the company in a report on Tuesday, May 7th. Wells Fargo & Company cut Integra LifeSciences from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $45.00 to $25.00 in a report on Tuesday, May 7th. Finally, StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $35.00.

Check Out Our Latest Research Report on IART

Insider Activity

In related news, Chairman Stuart Essig bought 52,641 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The shares were acquired at an average price of $28.49 per share, for a total transaction of $1,499,742.09. Following the completion of the acquisition, the chairman now owns 487,922 shares of the company’s stock, valued at approximately $13,900,897.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.10% of the company’s stock.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $28.31 on Monday. The business has a 50 day simple moving average of $30.53 and a 200 day simple moving average of $37.34. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. Integra LifeSciences Holdings Co. has a one year low of $22.36 and a one year high of $46.75. The company has a market capitalization of $2.23 billion, a PE ratio of 56.62, a price-to-earnings-growth ratio of 1.02 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting analysts’ consensus estimates of $0.55. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The business had revenue of $368.90 million during the quarter, compared to analysts’ expectations of $361.96 million. During the same period in the previous year, the firm earned $0.74 earnings per share. The firm’s quarterly revenue was down 3.2% compared to the same quarter last year. On average, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 3.03 EPS for the current fiscal year.

Integra LifeSciences Company Profile

(Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Featured Articles

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.